Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
February 20, 2024 07:14 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of...
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
February 05, 2024 07:51 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
February 01, 2024 08:15 ET
|
Clearmind Medicine Inc.
The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving Tel Aviv, Israel / Vancouver,...
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
January 16, 2024 11:19 ET
|
Clearmind Medicine Inc.
TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel...
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
January 11, 2024 09:28 ET
|
Clearmind Medicine Inc.
TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel...
Clearmind Medicine Completed Type A Meeting with the FDA
January 10, 2024 07:18 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
January 04, 2024 07:18 ET
|
Clearmind Medicine Inc.
The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with SciSparc's PEA Tel Aviv,...
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
December 14, 2023 08:26 ET
|
Clearmind Medicine Inc.
Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been CuredTel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
December 05, 2023 08:47 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023 08:14 ET
|
Clearmind Medicine Inc.
The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program Tel Aviv, Israel / Vancouver, Canada, Dec. 01, 2023 (GLOBE...